We conducted a randomized, double-blind investigation to determine whether enoximone affects the actions of dobutamine in patients taking {3 adrenoceptor antagonists. We studied sixteen patients with good ventricular function after coronary artery bypass operations. All patients were taking a {3 adrenoceptor antagonist. The patients received a standardized intravenous anaesthetic, which was maintained throughout the investigation. They received a masked infusion, containing either normal saline or enoximone. Haemodynamic data were recorded before, during, and after an infusion of dobutamine, which was given at three different rates.
Dobutamine is a synthetic catecholamine, which acts via !JI adrenoceptors to increase cardiac output, both by raising heart rate and by increasing the force of ventricular contraction. It exerts a secondary effect via !J2 adrenoceptors to produce vasodilation,,2. It has also been shown to act on ex adrenoceptors to produce vasoconstriction, but this is usually masked by its !J2 effects'. Enoximone is a selective inhibitor of phosphodiesterase-3. It promotes an inotropic response and peripheral vasodilation by increasing intracellular cyclic adenosine monophosphate (cAMP), but acts independently of the !J adrenoceptors,,4 Several studies have demonstrated the benefits of using either of these drugs to support the failing heart,-a.
In our unit, most of the patients who undergo coronary artery revascularization are taking a long-acting !JI selective adrenoceptor antagonist for the control of angina or hypertension. On the day of surgery they are given a dose of propranolol (non-selective !J adrenoceptor antagonist), because its shorter duration of action allows earlier recovery of !J adrenoceptor ·F.R.CA., Sir Humphrey Davy Department of Anaesthesia. tF.R.C.A., Sir Humphrey Davy Department of Anaesthesia. function after surgery. If patients need inotropic support afer cardiopulmonary bypass, dobutamine is usually the first drug chosen. The dose is titrated against systemic blood pressure and central venous pressure. It is not our practice to measure pulmonary artery pressure or cardiac output in patients who have good ventricular function before surgery. Patients who show an inadequate response to dobutamine are given enoximone.
1\vo recent studies··'o showed that the effect of dobutamine in patients with blocked !J adrenoceptors may not be advantageous, in that vasoconstriction mediated by ex adrenoceptors was shown. Systemic vascular resistance was increased and cardiac output was unchanged or reduced, which imposed an increased workload upon the myocardium. These studies were performed after the induction of anaesthesia, but before surgery. We set out to compare the doseresponse curves to dobutamine in two groups of patients, one group receiving an infusion of normal saline, and the other group receiving an infusion of enoximone. If the effects of the two drugs were additive, we expected the new curve to be parallel to the first, but transposed. If the effects of the two drugs were synergistic, we expected the two curves to diverge. We chose to study patients whose surgery was complete, but who were still anaesthetized, as these are the con-ditions when we would normally introduce inotropic therapy.
PATIENTS AND METHODS
We studied sixteen patients, with good left ventricular function, who underwent coronary artery bypass surgery. All patients were receiving maintenance therapy with a long-acting (31 selective adrenoceptor blocker (atenolol 13, metoprolol 2, bisoprolol 1), a calcium antagonist (diltiazem 13, nifedipine-SR 3) and a slow-release nitrate preparation. No patient was taking a diuretic. The study was approved by the hospital ethics committee and informed consent was obtained from each patient.
On the morning of surgery, the patients received their normal medication, except that a dose of 40 mg of propranolol was substituted for their normal (3 adrenoceptor antagonist. They were given lorazepam 1 mg per 20 kg body weight by mouth, two hours before the induction of anaesthesia. Each patient in the study was first on the operating list of the day. A 20-gauge cannula was placed in a radial artery and a 14-gauge cannula was placed in a peripheral vein, under local anaesthesia. A dose of 5 ml.kg I body weight of modified gelatin solution (Gelofusin) was given into the peripheral vein. Anaesthesia was induced with glycopyrronium 5 JLg.kg-l , fentanyl 10 JLg.kg I and propofol 0.5 mg.kg -I. The patient was paralysed with pancuronium 0.15 mg.kg-I . Anaesthesia was maintained by an infusion of fentanyl at 2 JLg.kg I.h -I, and a stepped infusion of propofol at 5 mg.kg -I.h I for 10 minutes, 4 mg.kg -I.h-I for 10 minutes and 3 mg.kg -I.h -I thereafter. The patient's trachea was intubated and the lungs were ventilated to eucapnia using oxygen in air. A triple lumen catheter (Vyggo, 10 cm) and a pulmonary artery (Pa) catheter (Baxter 7Fr.) were placed in the right internal jugular vein. The Pa catheter was advanced until the balloon wedged in a pulmonary artery, then the balloon was deflated and the catheter was withdrawn 5 cm. During the operation, episodes of systemic hypertension were treated by giving intravenous doses of fentanyl 5 JLg.kg-l . During bypass, while the patient's core temperature was less than 32 QC, the rate of propofol infusion was reduced to 1.5 mg.kg -I.h -I, as suggested by Manara and colleagues". Provided that the patients were weaned successfully from bypass without requiring inotropic support, they were then randomly allocated to receive either normal saline or enoximone by infusion. The trial solution was made up in a covered syringe by a third party, so that neither the anaesthetist nor the researcher were aware of the contents. The trial solution was infused via a dedicated port into the superior vena cava through opaque tubing to disguise the yellow colour of enoximone. During the first 20 minutes a volume was given that would deliver 0.5 mg.kg-I of enoximone, or an equivalent volume of normal saline, followed by an infusion at 5 JLg.kg-1 of enoximone, or an equivalent volume of normal saline. Intravenous fluid replacement was given as necessary to maintain the central venous pressure. Anaesthesia was continued with fentanyl 2 /lg.kg I.h I and propofol 3 mg.kg -I.h -I. An intravenous infusion of glyceryl trinitrate at I JLg.kg -I.min I was started, as a coronary vasodilator, and the patient was transferred to the intensive care unit. One hour was allowed after the transfer for the patient's cardiovascular status to become stable. The Pa catheter was advanced from the pulmonary artery until the balloon wedged. Cardiac output was measured by thermodilution and the mean of three consecutive readings was recorded. An arterial blood sample was analysed for sodium, potassium, pH, haematocrit and blood gas values. An intravenous infusion of dobutamine into the superior vena cava was started at 1 JLg.kg I.min -I. After 30 minutes, haemodynamic measurements and blood gas analysis were performed. The sequence was repeated for dobutamine infusion rates of 2 JLg.kg -I.min I and 4 /lg.kg I.min I, after which the dobutamine infusion was stopped. A final set of measurements was made 30 minutes later. The masked infusion was discontinued and the study was completed. During the study period, intravenous gelatine solution was given to maintain the central venous pressure at its initial value, and red blood cells were given to prevent the haematocrit falling below 25070. Potassium chloride in 5070 dextrose solution (5-20 mmols per 100 m!) was given at 1 ml.kg-1.h-1 , reviewed each hour, to maintain a serum potassium concentration of greater than 4 mmol.l I. The rate of ventilation, the tidal volume and the inspired fraction of oxygen were kept constant. The cardiac output and the systemic vascular resistance were derived from each set of cardiac output studies.
The results of the two groups of patients were compared using the unpaired Student's t test. The variance between the two groups, and within each group for the different rates of dobutamine infusion, was analysed, using ANOVA (MINITAB). A P value of less than 0.05 was chosen to indicate that differences were significant.
RESULTS
Sixteen patients were studied. The mean age for the group receiving saline was 58.8 years and the mean age of the group receiving enoximone was 63 years. The difference in age is not signi ficant. There was one female patient in each group. Two patients, both in the group receiving enoximone, were withdrawn from the trial. Patient number 6 suffered an anaphylactic reaction to an infusion of blood, requiring urgent resuscitation. Patient number 9 was accidentally given three times the intended loading dose of enoximone. Patient number 14 began to bleed from the internal mammary artery anastamosis, and required further surgery, which prevented us from studying the effect of dobutamine given at 4 Itg.kg-I.min-I . However, his cardiac filling pressures were maintained and the cardiac output values half an hour after stopping dobutamine, but before surgery, were obtained. The values of blood pH, serum potassium, Pa02 and PaC02 were stable throughout the study period for each patient. Patients receiving enoximone required on average 1500 ml more intravenous colloid than patients receiving normal saline to maintain their cardiac filling pressures. In the ITV during the period of study, both groups of patients had a mean core temperature of 35°C, which did not change with time. It was noted that patients did not rewarm while intravenous anaesthesia was maintained.
Patients receiving enoximone had significantly lower diastolic blood pressures (P<O.OOI) than patients receiving saline, but there was no significant difference between the systolic blood pressures of the two groups throughout the study period. Both groups showed significant increases in systolic and diastolic pressures with each increase in the rate of infusion of dobutamine (P<O.ool). The difference between the pressures before and after dobutamine was not significant. Patients receiving enoximone had significantly higher heart rates than patients recelVlng saline (P<O.ool), but neither group showed a significant change in heart rate in response to dobutamine. Patients receiving enoximone had significantly greater cardiac outputs (P<O.OOI) than patients receiving saline. There was no change in the response to dobutamine in either group. Patients receiving enoximone had a significantly lower systemic vascular resistance (P<O.ool) than patients receiving saline. Patients in both groups showed a significant, reversible increase in blood pressure in response to dobutamine, without a corresponding increase in cardiac output, indicating that peripheral vascular resistance had increased. This was confirmed by the increase in the value derived for systemic vascular resistance (P < 0.002). 
DISCUSSION
We completed studies on 14 of the 16 patients recruited to the project, all of whom had been taking a long-acting {3I selective adrenoceptor antagonist for more than one month before surgery. All had received a dose of 40 mg of propranolol (a non-selective (3 adrenoceptor antagonist) two hours before the start of anaesthesia. The group who received enoximone had a higher mean heart rate, a greater mean cardiac output and a lower mean diastolic blood pressure than the group who received saline, as was expected from previous studies'· 5 " .
In both groups, dobutamine produced reversible increases in blood pressure and systemic vascular resistance, but no significant changes in heart rate or cardiac output. Once dobutamine therapy ceased, the changes were promptly reversed. Enoximone did not affect the changes produced by dobutamine.
Early studies in dogs 1 showed that 8 J.tg.kg -I.min-I dobutamine exerted an arteriolar constrictor effect, mediated by a adrenoceptors, which could be blocked with phentolamine. Normally {3 adrenoceptor mediated effects predominate, but if these receptors are blocked, the a effect may be revealed I. If only {31 adrenoceptors were blocked with practolol, {32 mediated vasodilation was seen to balance the a effect I. However, muscle vascular beds were found to be dilated at the expense of vasocontriction in renal and splanchnic vascular beds. Tinker and colleagues' reported the effects of dobutamine in humans with low cardiac output states after cardiac surgery. They did not observe a vasoconstrictor effect, but did not describe what medication their patients were taking, if any, before operation. More recently, Lancon and colleagues 6 compared enoximone with dobutamine at variable doses after cardiac surgery. They found a similar haemodynamic profile for each drug, but also did not describe the preoperative medication. Gillbe and colleagues' compared enoximone 10 J.tg.kg-l.min-1 with dobutamine 10 J.tg.kg -I. min -I, but also gave no record of the preoperative medication. However, six of the ten patients receiving dobutamine in their study required further vasodilation with nitroglycerine or sodium nitroprusside. Tarnow and Komar 9 investigated the effect of dobutamine in two groups of patients, one taking {3 adrenoceptor antagonists and one not, during anaesthesia before cardiac surgery. They assessed the degree of {3 blockade using isoproterenol dose-response measurements in each patient. They found that either selective or non-selective {3 adrenoceptor blockade revealed a significant vasoconstrictor effect of dobutamine and prevented any inotropic or dilator effect. In their unblocked group, 4 J.tg.kg-I.min-I of dobutamine increased the heart rate by 18070. Boldt and colleagues lO reported a study comparing the effects of dobutamine 5 J.tg.kg-I.min-I and enoximone 0.5 mg.kg -I, single dose, given to patients treated with esmolol under anaesthesia before cardiac surgery. None of their patients were taking a {3 adrenoceptor antagonist before operation. Although esmolol is principally a selective {31 adrenoceptor antagonist, they noted that 5 J.tg.kg -I.min -I of dobutamine caused vasoconstriction, as shown by a rise in systemic vascular resistance and pulmonary artery wedge pressure, and a fall in cardiac output.
In contrast to these studies, our patients were studied after surgery. We did not assess the degree of {3 adrenoceptor antagonism by isoproterenol challenge 9 in our study, so we are not able to confirm that the antagonism remained constant throughout the period of the study in each patient. However, there was no chronotropic or inotropic response to dobutamine in any of our patients, nor was there a change in the baseline values of the heart rate or cardiac output during the period of study. Our results confirm the previous findings 9
• iO and we have shown that the action of enoximone did not facilitate the inodilator action of low doses of dobutamine in patients whose {3 adrenoceptors were blocked. The increase in blood pressure due to the a adrenergic action of dobutamine prevented us from using higher rates of infusion that might have generated sufficient {3 adrenergic action to overcome the {3 adrenoceptor blockade. Therefore we were unable to realise the original aim of the study, which was to explore any interaction between the inotropic actions of dobutamine and enoximone.
DOBUTAMINE PLUS ENOXIMONE, WITH {3 BLOCKADE 677
The majority of our patients presenting for coronary artery revascularization are taking long-acting (3 adrenoceptor antagonists. In common with other centres, it is not our routine practice to place pulmonary artery catheters in patients undergoing coronary artery surgery, unless their left ventricular function is known to be impaired. If hypotension is present at the end of surgery, an inotrope is titrated until an adequate blood pressure is achieved, on the assumption that the blood pressure is raised by increasing the cardiac output. We have shown that giving dobutamine in doses ranging from 1 to 4 /lg.kg-'.min-' to patients whose (3 adrenoceptors are blocked, produces the required increase in blood pressure not by increasing the cardiac output, which remains unchanged, but by increasing the systemic vascular resistance. The load on the left ventricle is increased. We have also shown that concurrent treatment with enoximone does not prevent or affect the vasoconstrictor activity of dobutamine in this group of patients. We suggest that cardiac output data should be used to guide therapy with dobutamine or any other inotrope, in the presence of (3 adrenoceptor blockade.
